NZM2

CODE: CBA-1378

NZM2 is an adherent cell line derived from a 47 year old male with melanoma metastatic to obturator lymph node

[Create a profile and sign in to view pricing and add to cart]

  • Description
  • Ask a Question

Description

Description: NZM2 is an adherent cell line derived from a 47 year old male with melanoma metastatic to obturator lymph node.

Description Key Words: Human metastatic melanoma 

Also Known As: No other names

Organism: Human (Homo sapiens

Tissue: melanoma metastatic to obturator lymph node

Growth Properties: Adherent

Doubling Time: 70 hours

Morphology: Epithelial

Growth Medium: This cell line was established by the depositor in: Alpha modified Minimum Essential Medium (MEM) supplemented with 5% Foetal Bovine Serum (FBS)”, 5 ug/ml Insulin, 5 ug/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5%O2, 5%CO2 and 90%N2.

At CellBank Australia it has been cultured in: Alpha modified Minimum Essential Medium (MEM) supplemented with 10% Foetal Bovine Serum (FBS)”, 5 ug/ml Insulin, 5 ug/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5%CO2.

ResuscitationRemove protective cryoflex layer around the ampoule prior to thawing. Thaw the ampoule by gently agitating in a 37°C waterbath; thawing should be rapid (around 2 minutes). A centrifugation step to remove the cryoprotectant after thawing is necessary for this cell line. 

Subculturing Procedure:

Medium Renewal: 3 times per week.

Subcultivation Ratio: 1:2 – 1:4 Seeding density 1.2 x104cells/cm2. Split subconfluent cultures(70-80%). Harvest the cells using 0.05% Trypsin/EDTA at 37°C for 5 minutes.

Culture Conditions: Incubate the culture at 37°C with 5% CO2.

Cryoprotectant Medium: 10% DMSO + 90% FCS

Handling Procedure for Frozen Cells: Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability.

Additional Information

  • Wild-type for BRAF, NRAS, TP53, PIK3CA, PTEN
  • CDKN2A/B deletion
  • Resistant to temozolomide;
  • MGMT expressed
  • aneuploid 1.77x diploid; chromosome number 71-78.

NZM1 and NZM2 were developed from the same patient whose malignant lymph nodes were excised 4 weeks apart.

Depositor: Professor Bruce Baguley – The University of Auckland, New Zealand

Reference:

Original Reference:

Marshall ES, Matthews JHL, Shaw JHF, Nixon J, Tumewu P, Finlay GJ, Holdaway KM, Baguley BC.

Radiosensitivity testing of human melanoma cell lines: comparison of [3H]-thymidine incorporation and soft agar clonogenic assays.

Eur J Cancer 1994; 30A: 1370-1376.

PubMed 7999427

Cellosaurus: CVCL_D823

Ask a Question

Have a question about this product? Our technical team is here to help.